Source: MarketWatchPublished: September 10, 2013  VANCOUVER, BRITISH COLUMBIA, Sep 10, 2013 (Marketwired via COMTEX) -- Verisante Technology, Inc. CA:VRS -4.84% (otcqx:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has completed the second phase prototype of a rapid Multispectral Imaging ("MSI") System for skin cancer detection. The MSI device is intended to assist medical professionals in the detection of all major forms of skin cancer. The device takes images of suspicious lesions with more than a dozen different wavelengths of light to capture real-time spectral images in a fraction of a second. These spectral images contain unique information about suspected skin lesions such as tissue oxygenation ratios, hemoglobin levels, melanin levels, scatter sizes, and other parameters. The prototype system is currently undergoing laboratory testing at the BC Cancer Agency Research Centre prior to starting in vivo data collection for training the predictive algorithm for the device. "Being able to extract the parameters collected by this MSI system could provide a strong predictive measurement for all major forms of skin cancer," said Dr. Haishan Zeng, a distinguished scientist in the Integrative Oncology Department at the BC Cancer Agency. Verisante licensed the MSI technology from the inventors, Dr. Haishan Zeng and Dr. Yasser Fawzy of the BC Cancer Agency, for skin cancer and oral cancer detection as part of a broader acquisition strategy to enhance the Company's intellectual property portfolio of different technologies that, in addition to MSI, include white light reflectance imaging, fluorescence imaging [...]